{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:08:59Z","timestamp":1791839339881,"version":"4.3.4"},"reference-count":118,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a leading driver of hepatocellular carcinoma (HCC) worldwide. A substantial proportion of MASLD-related HCC arises in the noncirrhotic liver, highlighting critical gaps in current surveillance strategies that rely primarily on fibrosis stage to define risk. Although the annual incidence of HCC in noncirrhotic MASLD is low and does not justify universal surveillance, the extraordinary global prevalence of MASLD translates into a considerable absolute burden of cancer. Accumulating evidence demonstrates that HCC risk in MASLD is modulated not only by histologic severity but also by metabolic comorbidities, particularly type 2 diabetes mellitus, which can significantly amplify cancer risk even in pre-cirrhotic stages. From both clinical and health economic perspectives, these observations underscore the need for more complex and targeted surveillance approaches. This review synthesizes current epidemiologic data, metabolic and histologic modifiers of HCC risk, emerging biomarkers, and predictive models in MASLD, with a focus on noncirrhotic disease. We discuss how integrated, precision-based risk assessment may identify high-risk MASLD subgroups and enable targeted, cost-effective surveillance strategies to mitigate the growing burden of MASLD-associated HCC.<\/jats:p>","DOI":"10.3390\/ijms27073241","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:09:54Z","timestamp":1775138994000},"page":"3241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0938-3011","authenticated-orcid":false,"given":"Emilie K.","family":"Mitten","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-1471","authenticated-orcid":false,"given":"Piero","family":"Portincasa","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Precision and Regenerative Medicine, University \u2018Aldo Moro\u2019 Medical School, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0400","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Baffy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"},{"name":"Department of Medicine, Section of Gastroenterology, VA Boston Healthcare System, 150 South Huntington Ave., Room 6A-46, Boston, MA 02130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"156004","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Taru, M.G., and Lupsor-Platon, M. (2023). Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography. Cancers, 15.","DOI":"10.3390\/cancers15164097"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1159\/000542805","article-title":"Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease","volume":"14","author":"Spiers","year":"2025","journal-title":"Liver Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated with Nonalcoholic Fatty Liver Disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.jhepr.2024.101160","article-title":"MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis","volume":"6","author":"Vitellius","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.metabol.2014.01.011","article-title":"Obesity-associated mechanisms of hepatocarcinogenesis","volume":"63","author":"Karagozian","year":"2014","journal-title":"Metabolism"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.metabol.2016.01.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma","volume":"65","author":"Zoller","year":"2016","journal-title":"Metabolism"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"HEP36","DOI":"10.2217\/hep-2020-0017","article-title":"Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma","volume":"7","author":"Nahon","year":"2020","journal-title":"Hepat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/hep.31157","article-title":"Risk of Cirrhosis and Hepatocellular Cancer in Patients with NAFLD and Normal Liver Enzymes","volume":"72","author":"Natarajan","year":"2020","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1136\/gutjnl-2025-334981","article-title":"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Lai","year":"2025","journal-title":"Gut"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer Risk in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Plaz Torres, M.C., Bodini, G., Furnari, M., Marabotto, E., Zentilin, P., Strazzabosco, M., and Giannini, E.G. (2020). Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. Cancers, 12.","DOI":"10.3390\/cancers12061422"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e0878","DOI":"10.1097\/HC9.0000000000000878","article-title":"Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system","volume":"10","author":"Ali","year":"2026","journal-title":"Hepatol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Paik, J.M., Hobbs, K., Gupta, A., Alkalbani, R.J., Reyes, M.A., and Younossi, Z.M. (2025). Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults: Insights From NHANES 2017 to 2023. J. Clin. Gastroenterol., ahead of print.","DOI":"10.1097\/MCG.0000000000002202"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jceh.2019.07.002","article-title":"Natural History of Non-Alcoholic Fatty Liver Disease: A Study with Paired Liver Biopsies","volume":"10","author":"Reddy","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s12325-024-03085-4","article-title":"Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database","volume":"42","author":"Luthra","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32434","article-title":"Risk factors for HCC in contemporary cohorts of patients with cirrhosis","volume":"77","author":"Kanwal","year":"2023","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lai, R., Barnett, S., Zhang, X., Kam, L.Y., Cheung, R., Xie, Q., and Nguyen, M.H. (2024). Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study. PLoS Med., 21.","DOI":"10.1371\/journal.pmed.1004479"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Toyoda, H., Tanwandee, T., Tangkijvanich, P., Tan, C.K., Cua, I.H., Alcantara-Payawal, D., Su, T.H., Huy, N.D.S., and Yamada, H. (2025). Utility of Biomarker Panels in the Surveillance and Monitoring of Hepatocellular Carcinoma: Consensus Statements from an International Delphi Panel. Liver Cancer, ahead of print.","DOI":"10.1159\/000550100"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1111\/jgh.16727","article-title":"Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility","volume":"39","author":"Balachandrakumar","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis: A Meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2025.06.025","article-title":"A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study","volume":"24","author":"Chun","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.21037\/hbsn-23-501","article-title":"Surveillance for hepatocellular carcinoma in non-alcoholic fatty liver disease patients: Towards personalized risk stratification","volume":"12","author":"Kim","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"goaf018","DOI":"10.1093\/gastro\/goaf018","article-title":"Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD","volume":"13","author":"Mi","year":"2025","journal-title":"Gastroenterol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101639","DOI":"10.1016\/j.jhepr.2025.101639","article-title":"Hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD)","volume":"8","author":"John","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","article-title":"Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study","volume":"79","author":"Ebrahimi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/liv.15819","article-title":"A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD","volume":"44","author":"Kim","year":"2024","journal-title":"Liver Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3803\/EnM.2024.2286","article-title":"Fatty Liver Index Dynamics as a Predictor of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus and Non-Cirrhotic Livers","volume":"40","author":"Cho","year":"2025","journal-title":"Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.cgh.2018.11.008","article-title":"Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients with Nonalcoholic Fatty Liver Disease Cirrhosis","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","article-title":"Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer","volume":"81","author":"Ahmed","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2024.03.004","article-title":"Early and accurate diagnosis of steatotic liver by artificial intelligence (AI)-supported ultrasonography","volume":"125","author":"Santoro","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Cerrito, L., Mignini, I., Ainora, M.E., Mosoni, C., Gasbarrini, A., and Zocco, M.A. (2023). Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. Cancers, 15.","DOI":"10.3390\/cancers15030637"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjsurg.2019.09.006","article-title":"Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis","volume":"219","author":"Kwak","year":"2020","journal-title":"Am. J. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study","volume":"2","author":"Hagstrom","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive Assessment of Liver Fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wilson, M.P., Singh, R., Mehta, S., Murad, M.H., Fung, C., and Low, G. (2025). Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis. Diagnostics, 15.","DOI":"10.3390\/diagnostics15131598"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MEG.0000000000002912","article-title":"Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: A systematic review and meta-analysis of aggregate and individual patient data","volume":"37","author":"Siriwong","year":"2025","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstrom","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100780","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: A longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e0487","DOI":"10.1097\/HC9.0000000000000487","article-title":"Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Kaplan","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","volume":"68","author":"Kim","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/apt.18346","article-title":"Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study","volume":"61","author":"Tan","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jhep.2022.06.016","article-title":"Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis","volume":"77","author":"Gracen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/liv.14301","article-title":"Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease","volume":"40","author":"Wong","year":"2020","journal-title":"Liver Int."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Sinn, D.H., Park, S.Y., Shin, H.J., Lee, H.W., Kim, B.K., Park, J.Y., Kim, D.Y., Ahn, S.H., and Oh, J.H. (2021). Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers, 13.","DOI":"10.3390\/cancers13184567"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep4.1852","article-title":"Predicting Liver-Related Outcomes in People with Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests","volume":"6","author":"Johnson","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease","volume":"19","author":"Petta","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"John, B.V., Bastaich, D.R., Deng, Y., Singal, A.G., Dahman, B., and Veterans Analysis of Liver Disease (VALID) Group of Investigators (2025). Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease. Hepatology, ahead of print.","DOI":"10.1097\/HEP.0000000000001498"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Walia, N., Hui, S., and Braude, M. (2025). Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD. Hepatology, ahead of print.","DOI":"10.1097\/HEP.0000000000001586"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstrom","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kanda, T., Sasaki-Tanaka, R., Abe, H., Kimura, N., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., and Tsuchiya, A. (2025). Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115164"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e70051","DOI":"10.1111\/liv.70051","article-title":"PNPLA3 I148M and Hepatocellular Carcinoma","volume":"45","author":"Tavaglione","year":"2025","journal-title":"Liver Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","article-title":"A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation","volume":"54","author":"Vujkovic","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.jhepr.2025.101485","article-title":"Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development","volume":"7","author":"Ghouse","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101508","DOI":"10.1016\/j.jhepr.2025.101508","article-title":"Genetic risk score correlates with immune profile and risk of HCC and cirrhosis development in Hispanics with MASLD","volume":"7","author":"Fu","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wei, X., Yang, C., Lin, Q., Qiu, M., Wen, Q., Zhou, Z., Jiang, Y., Chen, P., Liang, X., and Cao, J. (2024). Associations between modifiable risk factors and hepatocellular carcinoma: A trans-ancestry Mendelian randomization study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12525-x"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1038\/s41598-025-90744-3","article-title":"Bioinformatic analysis of molecular expression patterns during the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"15","author":"Lan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41416-025-02969-8","article-title":"The epigenetic basis of hepatocellular carcinoma\u2014Mechanisms and potential directions for biomarkers and therapeutics","volume":"132","author":"Lin","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-024-01755-x","article-title":"Metabolic memory: Mechanisms and diseases","volume":"9","author":"Dong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_88","first-page":"4238","article-title":"Genome-wide hypomethylation in hepatocellular carcinogenesis","volume":"61","author":"Lin","year":"2001","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Hoshida","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition","volume":"30","author":"Nakagawa","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.medj.2021.03.017","article-title":"A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis","volume":"2","author":"Fujiwara","year":"2021","journal-title":"Med"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2024.10.035","article-title":"Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis","volume":"168","author":"Fujiwara","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12328-021-01567-4","article-title":"Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM","volume":"15","author":"Shimizu","year":"2022","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/1940-6207.CAPR-24-0440","article-title":"Prediagnostic Plasma Metabolites Are Associated with Incident Hepatocellular Carcinoma: A Prospective Analysis","volume":"18","author":"Wilechansky","year":"2025","journal-title":"Cancer Prev. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/jgh.16326","article-title":"Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning","volume":"38","author":"Ito","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","article-title":"Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease","volume":"55","author":"Chen","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/jgh.16552","article-title":"Deciphering metabolic dysfunction-associated steatotic liver disease: Insights from predictive modeling and clustering analysis","volume":"39","author":"Mori","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e0016","DOI":"10.1097\/HC9.0000000000000016","article-title":"Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease","volume":"7","author":"Yi","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"155294","DOI":"10.1016\/j.metabol.2022.155294","article-title":"Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation","volume":"136","author":"Ye","year":"2022","journal-title":"Metabolism"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Atabaki-Pasdar, N., Ohlsson, M., Vinuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A.G., Thomas, E.L., Koivula, R.W., and Kurbasic, A. (2020). Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003149"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/17474124.2023.2191190","article-title":"Advances in our understanding of the molecular heterogeneity of fatty liver disease: Toward informed treatment decision making","volume":"17","author":"Pirola","year":"2023","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Zhou, B., Gong, N., He, Q., Huang, X., Zhu, J., Zhang, L., Huang, Y., Tan, X., Xia, Y., and Zheng, Y. (2023). Clustering of lifestyle behaviours and analysis of their associations with MAFLD: A cross-sectional study of 196,515 individuals in China. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-17177-3"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"McTeer, M., Applegate, D., Mesenbrink, P., Ratziu, V., Schattenberg, J.M., Bugianesi, E., Geier, A., Romero Gomez, M., Dufour, J.F., and Ekstedt, M. (2024). Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0299487"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Malik, S., Das, R., Thongtan, T., Thompson, K., and Dbouk, N. (2024). AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease. J. Clin. Med., 13.","DOI":"10.20944\/preprints202411.2084.v1"},{"key":"ref_106","first-page":"111737","article-title":"Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Transforming diagnosis and therapeutic approaches","volume":"32","year":"2026","journal-title":"World J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.21037\/jtd.2019.01.25","article-title":"Developing prediction models for clinical use using logistic regression: An overview","volume":"11","author":"Shipe","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.37737\/ace.22009","article-title":"Introduction to supervised machine learning in clinical epidemiology","volume":"4","author":"Ono","year":"2022","journal-title":"Ann. Clin. Epidemiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.02.004","article-title":"A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models","volume":"110","author":"Christodoulou","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2020.03.002","article-title":"Logistic regression was as good as machine learning for predicting major chronic diseases","volume":"122","author":"Nusinovici","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Romeo, M., Dallio, M., Napolitano, C., Basile, C., Di Nardo, F., Vaia, P., Iodice, P., and Federico, A. (2025). Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?. Diagnostics, 15.","DOI":"10.3390\/diagnostics15030252"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jhep.2021.09.025","article-title":"An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B","volume":"76","author":"Kim","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Minami, T., Sato, M., Toyoda, H., Yasuda, S., Yamada, T., Nakatsuka, T., Enooku, K., Nakagawa, H., Fujinaga, H., and Izumiya, M. (2023). Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals. J. Hepatol., ahead of print.","DOI":"10.1016\/j.jhep.2023.05.042"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.gastha.2024.01.007","article-title":"A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"3","author":"Sarkar","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Colak, C., Yagin, F.H., Algarni, A., Algarni, A., Al-Hashem, F., and Ardigo, L.P. (2025). Untargeted Lipidomic Biomarkers for Liver Cancer Diagnosis: A Tree-Based Machine Learning Model Enhanced by Explainable Artificial Intelligence. Medicina, 61.","DOI":"10.3390\/medicina61030405"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molimm.2024.07.015","article-title":"Identification and analysis of significant genes in nonalcoholic steatohepatitis-hepatocellular carcinoma transformation: Bioinformatics analysis and machine learning approach","volume":"174","author":"Yu","year":"2024","journal-title":"Mol. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/HEP.0000000000000904","article-title":"Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease","volume":"81","author":"Nakatsuka","year":"2025","journal-title":"Hepatology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:13:00Z","timestamp":1775275980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":118,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073241"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073241","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}